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Objectives: human vein graft stenoses are caused by intimal hyperplasia, a process which is characterised by extensive
degradation and accumulation of extracellular matrix. This study investigated the role of the matrix metalloproteinases
(MMPs) – the principal physiological mediators of extracellular matrix degradation – in the development of intimal
hyperplasia in cultured human long saphenous vein.
Design: experimental study.
Materials and methods: paired venous segments with the endothelium intact or denuded were cultured in standard
conditions for 14 days. At the termination of culture, MMPs were extracted from one half of the tissue, whist the
remainder of the vein was prepared for histological examination.
Results: stereologic analysis revealed that the endothelium intact veins developed a significantly thicker neointima when
compared to the denuded venous segments (20 lm v. 0 lm, p=0.006). Quantification of MMPs by substrate gel
enzymography demonstrated that the development of a neointima was associated with increased production of the
gelatinolytic MMP-9 (p=0.03) in intact veins. Immunocytochemistry showed that the MMP-9 localised to the internal
elastic lumina, which suggested a role in facilitating smooth-muscle-cell migration into the intima.
The role of MMPs-2 and -9 in intimal hyperplasia was further investigated by culturing intact venous segments with
a therapeutic concentration of doxycycline – a potent MMP inhibitor. These experiments demonstrated that a therapeutic
dose of doxycycline significantly reduced neointimal thickness (control 21 lm, doxycycline 10 mg/l–5.5 lm), in conjunction
with a significant reduction in the production of MMP-9.
Conclusions: these data suggest that elevated levels of MMPs may play a significant role in the development of human
intimal hyperplasia and that inhibition of these enzymes may offer a potential therapeutic strategy for the prevention of
hyperplastic lesions.
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Introduction vascular smooth-muscle cell in the restenotic process.
However, as yet, therapeutic agents aimed at reducing
Restenosis due to intimal hyperplasia remains one of smooth-muscle-cell proliferation, or targeted against
the commonest causes of failure following all forms of specific competence, or progression factors, have been
vascular reconstruction.1,2 This process is characterised ineffective in the clinical setting,7 and no effective
by proliferation of medial smooth-muscle cells, mi- strategy has been developed to prevent the de-
gration of these cells through the internal elastic lamina velopment of intimal hyperplasia following vascular
into the arterial lamina, and subsequent proliferation intervention.
to produce a hyperplastic lesion.3–6 To a large extent, In addition to the increased numbers of vascular
the cellular mechanics underlying the development of smooth-muscle cells, human restenotic lesions contain
vascular restenosis have been elucidated by ex- an abundance of extracellular matrix.8 Recent studies
periments on animal models subjected to arterial have suggested that interactions between the extra-
trauma. Findings from these studies have emphasised cellular matrix and surrounding smooth muscle cells
the dominant role of both growth factors and the may mediate smooth-muscle-cell behaviour, and po-
tentially provide an opportunity for therapeutic inter-
vention.9 Southgate et al.10,11 demonstrated that smooth-
* Please address all correspondence to: M. M. Thompson, De- muscle-cell proliferation and migration required de-partment of Surgery, Clinical Sciences Building, Leicester Royal
Infirmary, Leicester LE2 7LX, U.K. gradation of surrounding matrix proteins. This process
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is accomplished by secretion of specific matrix-de- study examined neointimal formation and MMP-2
and -9 production in intact and endothelium-denudedgrading enzymes from the smooth-muscle cells them-
selves. Several studies have now revealed that vascular vein segments. The second part of the study in-
vestigated the effect of a therapeutic concentration ofsmooth-muscle cells have the ability to digest all com-
ponents of the extracellular matrix through production an MMP-inhibiting tetracycline on these parameters.
and secretion of matrix metalloproteinases (MMPs).12–14
The MMPs are a family of zinc-dependent enzymes
that act as the principal physiological mediators of
Culture methodextracellular matrix degradation. They are char-
acterised according to their substrate specificity (col-
Segments of the long saphenous vein were obtainedlagenases, gelatinases and stromelysins), and their
from 10 patients undergoing arterial bypass graftingactivity is tightly regulated within vascular tissue by
and prepared for culture by a method previouslyboth serine proteases and specific tissue inhibitors of
described.8 For each patient, two segments of veinmetalloproteinases (TIMPs).15,16 Animal studies have
were cultured, one with the endothelium intact andsuggested that production and secretion of MMPs by
the other denuded of endothelium prior to culturing.vascular smooth muscle may mediate extracellular
Culture medium was replaced every 2–3 days, and atmatrix degradation and deposition, and may play a
the end of the 14-day culture period the segment wascrucial role in the development of intimal hyperplasia
divided into two equal halves. One half was fixed infollowing arterial injury.17,18 Although the evidence
4% paraformaldehyde for 18 hours, processed, em-from these animal studies is compelling, there is less
bedded in paraffin and sectioned to 4 lm thickness.data from human tissue to support a role for MMPs
The remaining half was immediately snap-frozen inin human vascular disease. However, recent studies
liquid nitrogen for subsequent metalloproteinase ex-have demonstrated the production and secretion of
traction and gelatin zymography.MMPs in human vascular tissue and have implicated
In a separate experiment, a further six paired seg-this enzyme system in the pathogenesis of both athero-
ments of saphenous vein were cultured with the endo-sclerosis19–22 and the development of arterial an-
thelium intact for 14 days. One segment served as aeurysms.23–27 It remains likely that MMPs will play a
control, and to the other a therapeutic concentrationcentral role in the formation of human restenotic le-
of doxycycline (10 lg/ml) was added to the culturesions, and evidence to support this hypothesis has
medium. This is equivalent to the mean plasma-troughbegun to emerge.28
level achieved by a single dose of 100 lg of oralThe present study investigated the role of the elasto-
doxycycline. At the end of the culture period, segmentslytic MMPs (MMP-2 and MMP-9) using an in vitro
were divided in half and processed as described above.model of human intimal hyperplasia. This model relies
upon the secretion of growth factors derived from the
intact endothelium to stimulate both smooth muscle
cell proliferation and migration. The end result is a
Gelatin zymographytypical neointimal lesion characterised by increased
numbers of intimal smooth muscle cells and an ac-
Metalloproteinases were extracted from the frozencumulation of extracellular matrix.8 The data from the
tissue as previously described.23,31 Briefly, frozen tissuepresent study suggested that enhanced production
was thawed over ice, weighed, chopped into 1 mm2of MMP-9 may be a crucial determinant of intimal
pieces and homogenised in buffer (urea 2 mM, Tris-thickening in this model and that inhibition of specific
HCl 50 mM pH 7.6, NaCl 137 mM, EDTA 1 g/l, Brij-MMPs may provide a potential therapeutic strategy
35 1/ml/1 and PMSF 0.1 mM – all Sigma, Poole, U.K.).to reduce late failure of arterial reconstructions.
The homogenate was then centrifuged at 10 000 g for
1 hour at 4 °C and the resulting supernatants were
dialysed (12–14 000 kDa) against a dialysing buffer
(Tris 25 mM pH 8.5, CaCl2 10 mM, 0.1% Brij-35, 0.1 mMMaterials and Methods
PMSF) for 12 hours at 4 °C. The protein concentration
of each sample was determined by the method ofExperimental design
Bradford,32 and normalised to 0.9 mg/ml so that all
bands fall into the linear range for scanning densi-This study utilised a previously well-validated organ
culture of human saphenous vein as a laboratory tometry. Equivalent protein loads (10 lg) were re-
solved by a non-reducing electrophoresis through amodel of intimal hyperplasia.8,29,30 The first part of the
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10% SDS-polyacrylamide gel impregnated with 1 mg/ subsequently detected by exposure of the membrane
to autoradiography film.31ml gelatin.25 As a positive control, conditioned medium
from a human fibrosarcoma cell line, HT-1080, was
also loaded onto each gel. Upon completion of the
separation, SDS was removed from the gels by in-
Immunohistochemistrycubation in 2.5% Triton X-100 (3·15 min), then they
were immersed for 18 hours in incubation buffer
Paraffin sections of 4 lm thickness were stained using(50 mM Tris-HCl, 10 mM CaCl and 0.05% Brij-35,
a combined monoclonal anti-smooth muscle actin/pH 7.4) at 37 °C. Gels were then fixed and stained in
Miller’s elastin stain35 in order to identify the layers0.1% Coomassie brilliant blue in 50% methanol/20%
of the vein wall. Measurements of neointimal thicknessacetic acid/30% double-distilled water for 2–3 hours.
were made using a computerised image analysis sys-Proteinases were visualised as clear bands of lysis
tem (Improvision, Coventry, U.K.) and making anagainst a dark background of intact substrate. The
average of 30 measurements across the entire lengthmolecular weight of each band was estimated by
of two consecutive sections for each vein segment ascomparison with the positions of known molecular
previously reported.8weight standards (Bio-Rad, Hemel Hempstead, U.K.).
Immunolocalisation of MMP-2 and MMP-9 in theThe relative density of each lytic band was determined
vascular wall was performed using specific mouse-from negative photographic images of gels with a
monoclonal antibodies (Oncogene Science) and an av-Pharmacia LKB Imagemaster scanning densitometer
idin–biotin complex horseradish peroxidase technique(Pharmacia LKB, St Albans, Herts, U.K.) and expressed
as previously described.31as a product of the optical density and area of the
band. The protein concentration utilised in this analysis
had been previously determined to be within the
linear range for densitometric quantification (data not Data analysis
shown). To allow for variation between zymographic
gels, all paired samples were run on the same gel, and Neointimal thicknesses were expressed as median
paired statistics used in analysis. No comparison was (range). Differences between groups were analysed
made between different gels. Studies in our laboratory using the Wilcoxon paired-rank test with significance
have demonstrated a correlation between MMP-9 pro- assumed at the 95% confidence level.
duction as assessed by zymography and enzyme- For substrate zymography the relative density of
linked immunoabsorbent assay (Amersham, Amer- gelatinolytic bands was quantified and compared be-
sham, U.K.) to be significant at the 1/1000 level. This tween samples run on the same gel. Differences be-
confirms previous comparisons of these techniques.33 tween groups were analysed using the Wilcoxon
paired rank test with significance assumed at the 95%
confidence level.
Western blotting
ResultsTo positively identify the MMPs in the tissue homo-
genates, the dialysates were fractioned on a 10% SDS-
Intact versus denuded veinpolyacrylamide gel and electrotransferred to a nitro-
cellulose membrane (Hybond ECL, Amersham, U.K.).
After washing the membranes with reconstituted non-
Neointimal thickness. As previously characterised, endo-fat dried milk (5% w/v)34 they were incubated with a
thelium-intact veins developed a cellular smoothmouse monoclonal antibody to MMP-2, TIMP-1 or
muscle actin-positive neointima, whereas removal ofTIMP-2 (Oncogene Science, Paris, France) for one hour.
the endothelium abolished or attenuated this re-After extensive washing with washing buffer (TBS,
sponse.8,29,30 The median (range) neointimal thickness0.1% Tween 20), the membranes were further in-
of intact veins was 20 (6–33) lm, and 0 (0–5) lm forcubated with a horseradish peroxide-labelled anti-
denuded veins. Median difference 20 lm, 95% con-mouse secondary antibody (Amersham, Slough, U.K.)
fidence interval 12.0 to 26.5, p=0.006 (Fig. 1).for 30 minutes. Following three further washes in
washing buffer, antigens were visualised by using a
Western blotting detection kit (ECL, Amersham, U.K.) Gelatin zymography. A representative gelatin zym-
ogram for intact and denuded veins is shown in Fig.which employs the emission of visible light which is
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Fig. 1. Scatter plot of neointimal thicknesses of paired segments of
intact and denuded human saphenous vein in culture. The median Fig. 3. Bar graph to show protease activity of cultured vein homo-
neointimal thickness of intact veins was 20 (range 6–33) lm, vs. 0 genates (median +95% confidence interval). Although there was
(range 0–5) lm for denuded veins. Median difference=20 lm, 95% no significant difference in the levels of total MMP-2 between intact
confidence interval=12.0 to 26.5, p=0.006. and denuded vein, there was a trend towards higher levels of active
MMP-2 in intact compared with denuded veins (p=0.08). Levels of
MMP-9 were significantly higher in intact veins than in denuded
veins, median scan density 1.42 vs. 1.26. Median difference=0.324,
95% confidence interval 0.041 to 0.596, p=0.03.
the presence of metalloproteinases. Immunoblotting
with specific monoclonal antibodies demonstrated im-
munoreactivity of the 92 kDa protein with anti MMP-
9 antibodies, whilst the 72 kDa and 66 kDa bands
reacted with an antibody to MMP-2 (data not shown).
From these data, and comparison with standard
weights, it was concluded that the 92 kDa band rep-
resented inactive MMP-9, with the 72 kDa and 66 kDa
proteins identified as the pro- and active forms of
MMP-2.
Densitometric analysis of all ten paired vein seg-
ments showed no significant differences in the levels
of pro-MMP-2 between intact and denuded veins.
There appeared to be a trend towards increased active
MMP-2 in intact veins, but this did not reach statistical
significance (p=0.08). The levels of MMP-9, however,
Fig. 2. Representative gelatin zymogram of homogenates for paired were significantly higher in endothelium-intact veins
intact and denuded cultured veins. Homogenates were run on the (median=1.42, range 0.949–2.6) than in denuded seg-
gel against a protein molecular weight marker, and bands of lysis
ments (median=1.26, range 0.552–1.805 – median dif-were observed at 92 kDa (MMP-9), 72 kDa (pro-MMP-2) and 66 kDa
(active MMP-2). Fibrosarcoma-derived HT-1080 cell served as posi- ference 0.324, 95% confidence interval 0.041 to 0.596,
tive controls. p=0.03) (Fig. 3). Western blotting for TIMP-1 and
TIMP-2 demonstrated no qualitative difference be-
tween the endothelium-denuded or intact veins (data2. Bands of lysis were consistently observed at 92 kDa,
82 kDa and 66 kDa. Inhibition of protease activity was not shown).
used to confirm the type of protease being detected
on the zymogram gels. For specific gels either 20 mM Immunocytochemistry. Immunohistochemical analysis
of vein sections localised MMP-2 to smooth muscleEDTA, 5 mM 1, 10 phenanthroline, or 1 mM phenyl-
methylsulphonylfluoride (PMSF) were included in the cells within the media and neointima confirming the
constitutive production of this protein. MMP-9 waszymogram buffer as required. Results demonstrated
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Fig. 4. (a) Combined Miller’s elastin and anti-smooth-muscle-cell actin stain of intact cultured vein. (b) Immunostaining for MMP-9 in
intact vein. Increased staining for MMP-9 can be observed in the region of the intima and internal elastic lamina. (c) Immunostaining for
MMP-9 in a doxycycline-treated vein. The intensity of staining is markedly reduced both in the neointima and internal elastic lamina.
The internal elastic lamina is marked by arrows in each case.
also demonstrated in the media and neointima, but Doxycycline-treated veins
staining was intense in the vicinity of the internal
elastic lamina of intact veins compared with denuded Neointimal thickness. Endothelium-intact veins cultured
in the presence of 10 lg/ml doxycycline developedsegments (Fig. 4a, b, c).
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Fig. 5. Scatter plot of neointimal thicknesses of paired segments of
vein cultured with and without 10 lg/ml doxycycline. The median Fig. 6. Line plot to show MMP-9 activity of veins cultured with
neointimal thickness of control veins was 21 (range 18–31) lm, and without doxycycline (10 lg/ml). MMP-9 was significantly re-
and 5.5 (range 3–110) lm for doxycycline treated veins. Median duced in the treated group. Median scan density of control veins
difference=17 lm, 95% confidence interval=12.5 to 23.0, p=0.036. 1.198 (range 0.810–3.693) vs. 0.607 (range 0.00–1.650). Median diff-
erence=0.9, 95% confidence interval=0.31 to 1.17, p=0.036.
significantly less neointima than untreated controls
(n=6 in each group). The median (range) neointimal
thickness of doxycycline-treated veins was 5.5 (3–11)
lm, versus 21 (18–31) lm in control veins (median
difference 17.0 lm, 95% confidence interval 12.5 to
23.0, p=0.036) (Fig. 5).
Gelatin zymography. Densitometric analysis of the six
paired vein segments cultured in the presence and
absence of doxycycline showed no significant dif-
ferences in the levels of pro- and active MMP-2. MMP-
9 was, however, significantly reduced in the doxy-
cycline-treated veins. Control veins median 1.198
(range 0.810–3.693) compared with doxycycline-
treated veins median 0.607 (range 0.00–1.650 – median
difference 0.90, 95% confidence interval 0.31 to 1.71,
p=0.036) (Figs 6 and 7). Western blotting for TIMP-1
and TIMP-2 demonstrated no qualitative difference
between the doxycycline-treated and control venous
segments (data not shown).
Immunocytochemistry. Immunohistochemical analysis
of vein sections treated with doxycycline demonstrated
a marked reduction in immunoreactivity when com-
pared to control segments (Fig. 4a and b).
Discussion
Balloon catheter injury of the rat carotid artery stim-
Fig. 7. Representative gelatin zymogram of homogenates for pairedulates the formation of intimal hyperplasia due to intact and doxycycline-treated veins. The doxycycline-treated group
demonstrated a reduction in MMP-9.smooth-muscle-cell proliferation and migration. Using
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this model, Bendeck et al.17 demonstrated that arterial MT-MMP is synthesised as a pro-enzyme and must
be cleaved during activation. Recent evidence hastrauma induced MMP-9 expression and activation
throughout the arterial wall within 6 hours of injury. suggested that MT-MMP may be activated by exposure
to extracellular plasmin.40 Previous studies have dem-Similarly, the activity of MMP-2 was enhanced, but
this appeared to be due to an increase in enzyme onstrated that smooth-muscle cells are capable of ex-
pressing both forms of plasminogen activator (uPAactivation rather than gene expression. Inhibition stud-
ies reduced the number of smooth-muscle cells mi- and tPA) in animal models of intimal hyperplasia.41 It
is therefore possible that plasmin cleavage of pro-MT-grating into the media, and it was suggested that, in
this model, gelatinase expression facilitated smooth- MMP is responsible for the increased activation of
MMP-2 demonstrated in the in vitro model of vein-muscle-cell migration from media to arterial intima.
Similar animal studies36 have suggested a central role graft stenosis. Preliminary unpublished observations
from our laboratory support a role for MT-MMP infor matrix metabolism in intimal hyperplasia but, at
present, data on human tissue is less established. activation of MMP-2, as immunocytochemistry pref-
erentially localises MT-MMP to the internal elasticThe present study utilised a well described in vitro
model of human vein-graft restenosis. The model relies lamina of venous segments developing a neointima in
organ culture.upon secretion of growth factors from an intact endo-
thelial monolayer to stimulate smooth-muscle-cell pro- Initial results from the present study suggested that
MMPs-2 and -9 may be intimately involved in theliferation and migration in a paracrine manner.30
Segments of vein cultured in the absence of an endo- generation of intimal hyperplasia, and may be effective
targets for pharmacological inhibition. This conceptthelial monolayer failed to develop a neointima. In
this model, veins cultured with an intact intimal layer was investigated by exposing the endothelial-intact
venous segments to a therapeutic concentration ofdemonstrated increased production of MMP-9, and a
trend towards increased activation of MMP-2 when doxycycline. Doxycycline belongs to the family of
tetracyclines and chemically-modified tetracyclines.compared to endothelial denuded veins. These find-
ings are similar to those reported by George et al.28 These groups of antibiotics have proven long-term
safety and efficacy in the treatment of acne vulgaris.who demonstrated increased secretion of MMP-9 and
MMP-2 in venous segments cultured for 12 days, when The drugs are frequently used in relatively low doses
for many months or years and have good side-effectcompared to freshly excised tissue. The study has not
addressed the importance of elevated MMP levels in profiles.42–44 Doxycycline non-selectively inhibits
MMPs by binding to the active zinc sites45 and alsothe different phases of intimal hyperplasia formation.
Further studies will be required to determine the by binding to a non-active calcium site which causes
conformational change46 and loss of enzymatic activity.relative roles of MMP production in both smooth-
muscle-cell migration and in the deposition and de- Secondary mechanisms of inhibition have also been
proposed which include a reduction in activation,47gradation of extracellular matrix in the neointima.
Furthermore, the possibility of fibroblast con- decreased gene expression48 and stabilisation of spe-
cific and non-specific inhibition.49 Additionally, doxy-tamination cannot be excluded from these studies.
The stimulus for increased MMP-9 production dur- cyclines and other tetracyclines have recently been
demonstrated to have an effect inhibiting the ex-ing formation of intimal hyperplasia remains un-
proven. MMP-9 expression may be upregulatd by pression of inducible nitric oxide synthase.50–52 As nitric
oxide has a significant effect in the formation of intimalnumerous growth factors and cytokines,14,37 and it is
likely that the increased production in the vein culture hyperplasia,53,54 it is tempting to speculate that doxy-
cycline may play a role in this pathway.model represents a response to endothelial-derived
paracrine agents. The increased activation of MMP-2 Exposure of the in vitro venous model to a thera-
peutic concentration of doxycycline significantly de-is more difficult to explain. MMP-2 is constitutively
expressed by vascular smooth-muscle cells and is creased both the production of MMP-9 and neointimal
thickness. The reduction in neointimal thickness wasphysiologically, activated by the relatively recently
described membrane-bound matrix metallo- particularly dramatic and exceeded the effect of alter-
native therapeutic agents previously tested in thisproteinases (MT-MMP), which contain a trans-
membrane domain within their structure.38 MT-MMP model (heparin and losartan).29,55 Prior animal studies
have demonstrated that MMP-inhibitors may reducebinds both proMMP-2 and TIMP-2 in a complex loc-
alised to the cell surface.39 Increased activation of MMP-9 production and smooth-muscle migration fol-
lowing balloon-catheter injury. However, Bendeck etMMP-2 therefore suggests either increased production
or activation of MT-MMP. al.18 revealed that inhibition of MMP-9 was not able
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